In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Mastercard Incorporated
(NYSE:MA), Halliburton Company (NYSE:HAL), Keysight Technologies
Inc. (NYSE:KEYS), Eli Lilly and Company (NYSE:LLY), Wabash National
Corporation (NYSE:WNC), and Regeneron Pharmaceuticals, Inc.
(NASDAQ:REGN), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified
analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
MA DOWNLOAD: http://Capital-Review.com/register/?so=MA
HAL DOWNLOAD: http://Capital-Review.com/register/?so=HAL KEYS
DOWNLOAD: http://Capital-Review.com/register/?so=KEYS LLY DOWNLOAD:
http://Capital-Review.com/register/?so=LLY WNC DOWNLOAD:
http://Capital-Review.com/register/?so=WNC REGN DOWNLOAD:
http://Capital-Review.com/register/?so=REGN
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Mastercard
Incorporated (NYSE:MA), Halliburton Company (NYSE:HAL), Keysight
Technologies Inc. (NYSE:KEYS), Eli Lilly and Company (NYSE:LLY),
Wabash National Corporation (NYSE:WNC), and Regeneron
Pharmaceuticals, Inc. (NASDAQ:REGN) on a fundamental level and
outlines the overall demand for their products and services in
addition to an in-depth review of the business strategy, management
discussion, and overall direction going forward. Several excerpts
from the recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in
this release was accessed March 22nd, 2019. Percentage calculations
are performed after rounding. All amounts in millions (MM), except
per share amounts.
-----------------------------------------
MASTERCARD INCORPORATED (MA) REPORT
OVERVIEW
Mastercard's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Mastercard reported revenue of $3,807.00MM
vs $3,312.00MM (up 14.95%) and analysts estimated basic earnings
per share $0.88 vs $0.23 (up 282.61%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Mastercard reported
revenue of $14,950.00MM vs $12,497.00MM (up 19.63%) and analysts
estimated basic earnings per share $5.63 vs $3.67 (up 53.41%).
Analysts expect earnings to be released on May 1st, 2019. The
report will be for the fiscal period ending March 31st, 2019. The
reported EPS for the same quarter last year was $1.50. The
estimated EPS forecast for the next fiscal year is $8.90 and is
expected to report on January 30th, 2020.
To read the full Mastercard Incorporated (MA) report, download
it here:
http://Capital-Review.com/register/?so=MA
-----------------------------------------
HALLIBURTON COMPANY (HAL) REPORT OVERVIEW
Halliburton's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Halliburton reported revenue of $5,936.00MM
vs $5,940.00MM (down 0.07%) and analysts estimated basic earnings
per share $0.76 vs -$0.94. For the twelve months ended December
31st, 2018 vs December 31st, 2017, Halliburton reported revenue of
$23,995.00MM vs $20,620.00MM (up 16.37%) and analysts estimated
basic earnings per share $1.89 vs -$0.53. Analysts expect earnings
to be released on April 22nd, 2019. The report will be for the
fiscal period ending March 31st, 2019. Reported EPS for the same
quarter last year was $0.41. The estimated EPS forecast for the
next fiscal year is $2.06 and is expected to report on January
28th, 2020.
To read the full Halliburton Company (HAL) report, download it
here:
http://Capital-Review.com/register/?so=HAL
-----------------------------------------
KEYSIGHT TECHNOLOGIES INC. (KEYS) REPORT
OVERVIEW
Keysight Technologies' Recent Financial
Performance
For the three months ended January 31st, 2019 vs
January 31st, 2018, Keysight Technologies reported revenue of
$1,006.00MM vs $837.00MM (up 20.19%) and analysts estimated basic
earnings per share $0.61 vs $0.50 (up 22.00%). For the twelve
months ended October 31st, 2018 vs October 31st, 2017, Keysight
Technologies reported revenue of $3,878.00MM vs $3,189.00MM (up
21.61%) and analysts estimated basic earnings per share $0.88 vs
$0.57 (up 54.39%). Analysts expect earnings to be released on May
29th, 2019. The report will be for the fiscal period ending April
30th, 2019. Reported EPS for the same quarter last year was $0.77.
The estimated EPS forecast for the next fiscal year is $4.07 and is
expected to report on November 19th, 2019.
To read the full Keysight Technologies Inc. (KEYS) report,
download it here:
http://Capital-Review.com/register/?so=KEYS
-----------------------------------------
ELI LILLY AND COMPANY (LLY) REPORT OVERVIEW
Eli Lilly's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Eli Lilly reported revenue of $6,438.60MM
vs $6,160.70MM (up 4.51%) and basic earnings per share $1.10 vs
-$1.58. For the twelve months ended December 31st, 2018 vs December
31st, 2017, Eli Lilly reported revenue of $24,555.70MM vs
$22,871.30MM (up 7.36%) and analysts estimated basic earnings per
share $3.14 vs -$0.19. Analysts expect earnings to be released on
April 23rd, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was $1.34. The estimated EPS forecast for the next fiscal year is
$6.46 and is expected to report on February 5th, 2020.
To read the full Eli Lilly and Company (LLY) report, download it
here:
http://Capital-Review.com/register/?so=LLY
-----------------------------------------
WABASH NATIONAL CORPORATION (WNC) REPORT
OVERVIEW
Wabash National's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Wabash National reported revenue of
$610.20MM vs $543.44MM (up 12.28%) and analysts estimated basic
earnings per share $0.22 vs $0.84 (down 73.81%). For the twelve
months ended December 31st, 2018 vs December 31st, 2017, Wabash
National reported revenue of $2,267.28MM vs $1,767.16MM (up 28.30%)
and analysts estimated basic earnings per share $1.22 vs $1.88
(down 35.11%). Analysts expect earnings to be released on May 7th,
2019. The report will be for the fiscal period ending March 31st,
2019. The reported EPS for the same quarter last year was $0.28.
The estimated EPS forecast for the next fiscal year is $1.43 and is
expected to report on February 4th, 2020.
To read the full Wabash National Corporation (WNC) report,
download it here:
http://Capital-Review.com/register/?so=WNC
-----------------------------------------
REGENERON PHARMACEUTICALS, INC. (REGN) REPORT
OVERVIEW
Regeneron Pharmaceuticals' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Regeneron Pharmaceuticals reported revenue
of $1,927.80MM vs $1,582.42MM (up 21.83%) and analysts estimated
basic earnings per share $7.59 vs $1.61 (up 371.43%). For the
twelve months ended December 31st, 2018 vs December 31st, 2017,
Regeneron Pharmaceuticals reported revenue of $6,710.80MM vs
$5,872.20MM (up 14.28%) and analysts estimated basic earnings per
share $22.65 vs $11.27 (up 100.98%). Analysts expect earnings to be
released on May 2nd, 2019. The report will be for the fiscal period
ending March 31st, 2019. The reported EPS for the same quarter last
year was $3.98. The estimated EPS forecast for the next fiscal year
is $20.78 and is expected to report on February 5th, 2020.
To read the full Regeneron Pharmaceuticals, Inc. (REGN) report,
download it here:
http://Capital-Review.com/register/?so=REGN
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Nicole Garrens, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Wabash National (NYSE:WNC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Wabash National (NYSE:WNC)
Historical Stock Chart
From Sep 2023 to Sep 2024